EdgeScore

XBIT · Nasdaq

XBiotech Inc.: financial statements

Insufficient data · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2018: $0Net income 2018: -$21.1M2018Revenue 2019: $0Net income 2019: $669M2019Revenue 2020: $44.0MNet income 2020: -$11.2M2020Revenue 2021: $18.4MNet income 2021: -$17.4M2021Revenue 2022: $4.0MNet income 2022: -$32.9M2022Revenue 2023: $0Net income 2023: -$24.6M2023
RevenueNet income

Operating and free cash flow

Operating cash flow 2018: -$16.5MFree cash flow 2018: -$16.7M2018Operating cash flow 2019: -$18.3MFree cash flow 2019: -$18.5M2019Operating cash flow 2020: -$65.1MFree cash flow 2020: -$68.9M2020Operating cash flow 2021: $69.4MFree cash flow 2021: $65.9M2021Operating cash flow 2022: -$14.8MFree cash flow 2022: -$15.4M2022Operating cash flow 2023: -$18.7MFree cash flow 2023: -$19.1M2023
Operating cash flowFree cash flow

Margins

Gross 2020: 21.5%Gross 2021: 68.4%Gross 2022: 83.8%Operating 2020: -41.5%Operating 2021: -136.4%Operating 2022: -860.1%Net 2020: -25.5%Net 2021: -94.7%Net 2022: -820.4%201820192020202120222023
GrossOperatingNet

Returns

ROE 2018: -51.1%ROE 2019: 88.5%ROE 2020: -3.2%ROE 2021: -6.5%ROE 2022: -13.7%ROE 2023: -11.2%ROIC 2018: -82.1%ROIC 2019: -87.3%ROIC 2020: -21.0%ROIC 2021: -23.9%ROIC 2022: -58.5%ROIC 2023: -58.1%ROA 2018: -47.7%ROA 2019: 81.9%ROA 2020: -3.2%ROA 2021: -6.3%ROA 2022: -13.4%ROA 2023: -10.8%201820192020202120222023
ROEROICROA

Income statement

USD201820192020202120222023Last year
Revenue$0$0$44.0M$18.4M$4.0M$0-100%
Gross profit$0$0$9.4M$12.6M$3.4M$0-100%
Operating income-$21.0M-$31.2M-$18.3M-$25.1M-$34.5M-$37.5M-9%
EBITDA-$18.6M-$28.9M-$16.0M-$22.4M-$31.9M-$35.8M-12%
Interest expense—————$0
Profit before tax-$21.1M$718M-$12.8M-$25.5M-$33.6M-$24.3M+28%
Income tax$0$49.8M-$1.6M-$8.0M-$688K$244K+135%
Net income-$21.1M$669M-$11.2M-$17.4M-$32.9M-$24.6M+25%

Cash flow

USD201820192020202120222023Last year
Operating cash flow-$16.5M-$18.3M-$65.1M$69.4M-$14.8M-$18.7M-26%
Capital expenditure$122K$204K$3.7M$3.5M$585K$362K-38%
Free cash flow-$16.7M-$18.5M-$68.9M$65.9M-$15.4M-$19.1M-24%
Depreciation & amortization$2.4M$2.4M$2.2M$2.6M$2.6M$1.7M-35%

Balance sheet

USD201820192020202120222023Last year
Cash$15.8M$715M$237M$237M$157M$200M+27%
Current assets$17.0M$716M$326M$247M$220M$202M-8%
Total assets$44.3M$817M$354M$275M$246M$227M-8%
Current liabilities$2.9M$60.2M$4.0M$3.5M$4.1M$6.1M+50%
Total liabilities$2.9M$61.2M$5.1M$5.8M$5.7M$7.8M+36%
Shareholders' equity$41.4M$756M$349M$269M$240M$219M-9%
Net debt-$15.8M-$715M-$237M-$237M-$157M-$200M-27%

Dividend profile

The latest annual report shows no dividend to shareholders.

Dividends

USD201820192020202120222023Last year
Dividends paid—$0$0$75.0M$0—
Dividend per share—0.000.002.500.00—
Dividends / net income—0.0%————
Dividends / free cash flow———113.8%——

Ratios

201820192020202120222023Last year
Gross margin——21.5%68.4%83.8%—
Operating margin——-41.5%-136.4%-860.1%—
Net margin——-25.5%-94.7%-820.4%—
Return on equity-51.1%88.5%-3.2%-6.5%-13.7%-11.2%
Return on assets-47.7%81.9%-3.2%-6.3%-13.4%-10.8%
Return on invested capital-82.1%-87.3%-21.0%-23.9%-58.5%-58.1%
Current ratio5.7811.9081.8071.4954.0733.07
Quick ratio5.7811.9081.8071.4954.0733.07

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.